Daix (France), Long Island City (New York, United States), January 30, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of small molecules administered by for the treatment of non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical need, today announces the half-yearly results of its liquidity agreement entered into with Kepler Cheuvreux.
Under the liquidity contract relating to the shares of the Company entrusted to Kepler Cheuvreux, on the date of
December 31, 2022, the following resources appeared in the liquidity account: